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Aims We hypothesized that nebivolol, a beta-blocker with nitric oxide-releasing properties, could favourably affect exer-
cise capacity in patients with heart failure and preserved left ventricular ejection fraction (HFPEF).
Methods and
results
A total of 116 subjects with HFPEF, in New York Heart Association (NYHA) functional class II– III, with left ventricu-
lar ejection fraction (LVEF) .45%, and with echo-Doppler signs of LV diastolic dysfunction, were randomized to
6 months treatment with nebivolol or placebo, following a double-blind, parallel group design. The primary endpoint
of the study was the change in 6 min walk test distance (6MWTD) after 6 months. Nebivolol did not improve
6MWTD (from 420+143 to 428+ 141 m with nebivolol vs. from 412+ 123 to 446+119 m with placebo,
P ¼ 0.004 for interaction) compared with placebo, and the peak oxygen uptake also remained unchanged
(peakVO2; from 17.02+ 4.79 to 16.32+3.76 mL/kg/min with nebivolol vs. from 17.79+5.96 to 18.59+5.64
mL/kg/min with placebo, P ¼ 0.63 for interaction). Resting and peak blood pressure and heart rate decreased with
nebivolol. A significant correlation was found between the change in peak exercise heart rate and that in
peakVO2 (r ¼ 0.391; P ¼ 0.003) for the nebivolol group. Quality of life, assessed using the Minnesota Living with
Heart FailureTM Questionnaire, and NYHA classification improved to a similar extent in both groups, whereas N-ter-
minal pro brain natriuretic peptide (NT-pro BNP) plasma levels remained unchanged.
Conclusions Compared with placebo, 6 months treatment with nebivolol did not improve exercise capacity in patients with
HFPEF. Its negative chronotropic effect may have contributed to this result.
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Introduction
Approximately 50% of patients with heart failure (HF) have a pre-
served left ventricular (LV) ejection fraction (EF) and their inci-
dence and prevalence are increasing.1 Patients with HF
and preserved EF (HFPEF) differ from subjects with HF and
reduced LVEF (HFREF) with respect to demographic and clinical
characteristics.2 –5 However, symptoms, prognostic variables,
hospitalization, and mortality rates are similar.1– 3,5– 11 Large trials
enrolling patients with HFPEF have yielded unsatisfactory
results,10,12–14 and no specific drug regimen is recommended by
current guidelines.15
Because of their benefits in terms of LV remodelling and out-
comes, beta-blockers have become standard treatment in patients
with HFREF. However, most studies have either not evaluated or
have shown a neutral result for an effect on maximal exercise
capacity.16 From a theoretical standpoint, blood pressure
control, increased diastolic filling time, and protection from ischae-
mia, resulting from beta-blockers, might also be useful for the
treatment of HFPEF. In one study, beta-blocker therapy has been
associated with decreased myocardial collagen volume fraction,
reduced cardiac myocyte diameter, and down-regulated expres-
sion of stimulatory G protein, all effects which may improve
cardiac diastolic function, in patients with HFPEF.17
The Study of Effects of Nebivolol Intervention on Outcomes
and Rehospitalization in Seniors With Heart Failure (SENIORS)12
is the only prospective beta-blocker trial which included patients
with HFPEF and focused on hard endpoints. The effects of nebivo-
lol on the primary endpoint, as well as secondary endpoints, were
similar in patients with LVEF ,35% and those with higher LVEF.11
The cut-off of 35% for defining the HFPEF group in that study was
lower than usually applied.4 In addition, SENIORS did not include
formal exercise capacity as an endpoint.
Nebivolol is a highly selective blocker of beta-1 adrenergic
receptors with associated vasodilatory effects mediated by nitric
oxide (NO) release and beta-3 adrenergic receptor stimula-
tion.18– 21 NO release has been shown to favour relaxation at
the cardiac level so that lower LV pressure is achieved during
diastole.22,23 Haemodynamic studies have confirmed these find-
ings,19,21,23 and have also shown improved exercise tolerance
with nebivolol, compared with traditional beta-blockers.24
We therefore hypothesized that a beta-blocker with
NO-releasing properties, such as nebivolol, could favourably
affect exercise tolerance in patients with HFPEF. This paper pre-
sents the results of the effects on exercise capacity of the phase
IIIb study: ‘Effects of Long-term Administration of Nebivolol on
the clinical symptoms, exercise capacity, and left ventricular func-
tion of patients with Diastolic Dysfunction (ELANDD)’, a rando-
mized, double-blind, multicentre, parallel group, placebo-
controlled trial designed to investigate the effects of nebivolol in
patients with HFPEF (Study ID MeBN/02/Neb-DHF/001).
Methods
A complete description of the study design and the endpoint definition
has been published previously.25
Inclusion and exclusion criteria
To be included into the study, patients had to fulfil the following
criteria: willing and able to sign the informed consent form and
comply with the requirements of the study, aged ≥40 years, have a
documented history of HF and persistent symptoms during effort
[New York Heart association (NYHA) class II– III ], an LVEF .45%,
and LV end-diastolic internal diameter ,3.2 cm/m2 or LV end-diastolic
volume index ,102 mL/m2 by echocardiography, radionuclide ventri-
culography, or nuclear magnetic imaging, or any abnormality of LV
diastolic function documented by echocardiography, according to the
guidelines of the European Study Group on Diastolic Heart Failure.26
This last inclusion criterion was revised in April 2007 following the
online publication of the new consensus statement on the diagnosis
of HFPEF by the European Society of Cardiology.4 Accordingly, an E/
E‘ ratio .15 at tissue Doppler echocardiography was required as an
inclusion criterion. Patients with an E/E‘ ratio between 8 and 15
could be included when additional abnormalities of diastolic function
were found. These included an E/A ratio ,0.5 and/or a deceleration
half-time .280 ms in patients older than 50 years, and/or a duration
of reverse pulmonary vein atrial systole flow–mitral valve atrial wave
flow .30 ms, and/or a left atrial volume index .40 mL/ m2, and/or
an increased LV mass index.4 Exclusion criteria were also described
in detail in the design paper.25 They included a recent (,3 months)
acute coronary or cerebrovascular ischaemic event, exercise-induced
myocardial ischaemia, major contraindications to beta-blocker treat-
ment, or ongoing treatment with beta-blockers, verapamil, or
diltiazem.
Procedures
Patients were assigned to placebo or nebivolol in a double-blinded
manner according to a computer-generated 1:1 randomization
scheme. Nebivolol was started at 2.5 mg/day and gradually up-titrated
to 10 mg/day over a period of 5 weeks. Down-titration to lower doses
was allowed if the higher dose was not tolerated. Treatment at main-
tenance doses was continued for an additional 21 weeks (6 months of
treatment in total). Ongoing treatment with other drugs was main-
tained throughout the study.
Clinical examination, including blood pressure and heart rate mea-
surements, 6 min walk test (6MWT), cardiopulmonary exercise test,
and Doppler echocardiography were performed at baseline, within 1
week before randomization, and after 21 weeks of maintenance treat-
ment with the study drug. Procedures are described in detail in the
design paper.25
The primary endpoint of the study was the change from baseline in
the distance walked during the 6MWT after 6 months of treatment
with nebivolol vs. placebo. Additional secondary endpoints are
shown in the design paper.25 The present paper is focused on the
primary endpoint and the results on exercise capacity measurements.
Statistics
The size of the study group was calculated assuming a similar impair-
ment of 6MWT distance (6MWTD) and exercise capacity in patients
with HFPEF, compared with those with low LVEF,24 and a similar
improvement with nebivolol in patients with HFPEF, compared with
that found with other beta-blockers in patients with low LVEF.27
Thus, assuming a 10% drop-out rate and a 15% difference (70 m) in
the increase in the 6MWTD between the nebivolol and the placebo
treatment groups, we calculated that a sample size of 118 patients
(59 in each group) would have detected a difference of 70 m, at an
SD of 140 m, as statistically significant at a ¼ 0.05 (two tailed) and
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b ¼ 0.20 (power 80%) for the comparison of the change of the
6MWTD between the two study groups.
Pre-treatment characteristics were compared between the nebivo-
lol and placebo groups by Student’s t-test and/or analysis of variance
(ANOVA) for continuous variables and the Cochran–Mentel–
Haenszel test or Fisher’s exact test for categorical variables. Efficacy
endpoints were evaluated using the intent-to-treat (ITT) method,
applying the last observation carried forward method for patients
enrolled who were not reassessed after 6 months.
The changes from baseline in the two treatment groups were com-
pared by two-way ANOVAs. Data are presented as mean+SD unless
otherwise specified. Namely, N-terminal pro brain natriuretic peptide
plasma levels are shown as median as their distribution was not
normal. Analysis was performed using SAS version 9 or higher. The
recorded adverse events were coded according to the Medical
Dictionary for Regulatory Activities (MedDRA)w terminology and
compared for both treatment groups using Fisher’s exact test.
Results
A total of 116 subjects were enrolled in 12 centres from eight
countries, with 57 patients assigned to nebivolol and 59 to
placebo. Due to early withdrawal for side effects, poor tolerance,
or lack of compliance, 6 month reassessment was performed in 93
patients (42 on nebivolol and 51 on placebo, Figure 1). Ten patients
dropped out during the titration phase, two for withdrawal of
consent and eight for AEs. All the 93 patients who completed
the study achieved the target dose of the study drug which, in
the case of the 42 patients on nebivolol, corresponded to 5 mg
daily or, if the patient could tolerate it, to 5 mg b.i.d. Seven patients
assigned to nebivolol had a dose reduction to 2.5 mg daily on at
least one visit because of lack of tolerance but completed the
study on nebivolol 5 mg daily. No death or hospitalization
occurred during follow-up in any patient.
Patients characteristics
Clinical characteristics of the two study groups are shown in
Table 1. Mean age was 66 years and most patients were female
(65%), with a history of hypertension and with a relatively high
body mass index of 30. No differences were found between the
two study groups with respect to baseline variables, with the
exception of a higher proportion of chronic obstructive pulmonary
disease (COPD) among the patients assigned to nebivolol (16% vs.
7%, P ¼ 0.032).
Heart rate and blood pressure data, measured during the clinical
visits at baseline and at the end of the study, are shown in Table 2.
Primary endpoint
The 6MWTD increased numerically from 420+143 m to 428+
141 m with nebivolol, with a mean increase from baseline of
+7.8+34.5 m (P ¼ 0.094). This change was significantly smaller
than the observed difference for the placebo group (+33.54+
63.8 m, P ¼ 0.0001 vs. baseline, and P ¼ 0.004 for interaction;
Table 3).
Cardiopulmonary exercise test
Peak oxygen uptake (peakVO2) decreased slightly in the nebivolol
group, and increased in the placebo group, without reaching stat-
istical significance (Table 3). Exercise duration and peak workload
did not show any difference between the two groups after 6
months treatment. Resting and peak heart rate, as well as systolic
blood pressure decreased significantly from baseline in the nebivo-
lol group, without a change in the placebo arm (Table 3).
A significant correlation was found between the change in peak
exercise heart rate and the change in peakVO2 (r ¼ 0.391; P ¼
0.003, Figure 2) for the patients treated with nebivolol. This did
not occur in the placebo group (data not shown).
Figure 1 Patient flow diagram.
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New York Heart Association class and
quality of life
NYHA functional class improved from baseline in both groups
(from 2.19+0.44 to 1.93+0.50 for nebivolol: P ¼ 0.0001; from
2.22+0.42 to 1.95+ 0.60 for placebo: P ¼ 0.0003) without a
significant difference between the two treatment arms (P ¼
0.854 for interaction).
The improvement from baseline in quality of life, measured with
the Minnesota Living with Heart Failure Questionnaire, was of a
similar magnitude in the nebivolol (from 27+17 tot 23+21,
P ¼ 0.009) and placebo group (from 29+19 to 24+18, P ¼
0.007). No difference between the two treatment groups was
observed (P ¼ 0.697 for interaction), both when the overall
score was considered and when the physical and the emotional
dimension scores were considered separately (data not shown).
N-terminal pro brain natriuretic peptide
NT-proBNP plasma levels slightly increased from baseline in the
nebivolol group [median (range) from 147 pg/ mL (9–3577) to
162 pg/ mL (27–5158), P ¼ 0.228], whereas they slightly
decreased in the placebo group [from 126 pg/ mL (15–2055) to
99 pg/ mL (16–2899), P ¼ 0.413], with no significant difference
between the nebivolol and placebo arm (P ¼ 0.878 for
interaction).
Adverse events
The number of subjects who experienced at least one drug-related
AE was higher in the nebivolol group (20 subjects, 35.1%),
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 1 Clinical characteristics of the patients
Variables Nebivolol (n5 57) Placebo (n 5 59) P-value
Age (years) 66.5+9.8 65.3+11.3 0.389
Gender, males, n (%) 20 (35) 21 (36) .0.999
Aetiology, n (%)
Coronary artery disease, n (%) 10 (17) 12 (20) 0.676
Hypertension, n (%) 49 (86) 51 (86.4) 0.981
Body mass index (kg/m2) 30.3+4.5 30.2+4.9 0.397
Diabetes, n (%) 12 (21) 12 (20) 0.999
Hyperlipidaemia, n (%) 32 (56) 33 (56) 0.832
Smoking habits, n (%) 8 (14) 10 (17) 0.814
COPD, n (%) 9 (16) 4 (7) 0.032
NYHA class, II/III, n (%) 44 (77)/12 (21) 46 (78)/13 (22) 0.771
Serum BUN, mmol/L 13.6+9.1 12.6+7.9 0.077
Serum creatinine, mmol/L 88.5+33.1 85.8+25.1 0.463
6MWTD, m 420+143 412+123 0.586
Peak VO2, mL/kg/min 17.02+4.79 17.79+5.96 0.073
LV ejection fraction (%) 61.9+7.8 63.2+9.2 0.428
Left atrial dilatation (% of patients) 56.1 63.4 0.68
E/A ratio 0.8+0.18 0.9+0.21 0.927
E/E’ (E’: sept + lat mitr ann/2) 11.1+4.2 11.0+4.0 0.707
Concomitant medication
Diuretics, n (%) 28 (49) 32 (54) 0.71
ACE inhibitors/sartans, n (%) 43 (75) 47 (80) 0.659
Calcium channel blockers, n (%) 11 (19) 21 (36) 0.062
Hypolipidaemic drugs, n (%) 26 (46) 31 (53) 0.465
Antidiabetic agents, n (%) 12 (21) 12 (20) .0.999
ACE, angiotensin-converting enzyme; BUN, blood urea nitrogen; COPD, chronic obstructive pulmonary disease.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 2 Haemodynamic variables measured at rest
during the clinical assessments
Variables Nebivolol Placebo P-value
Heart rate at rest, b.p.m.
Baseline 73+14 73+11 0.397
6 months 67+8 75+13 ,0.001
Systolic BP at rest, mmHg
Baseline 134+21 133+18 0.992
6 months 127+16 129+18 0.390
Diastolic BP at rest, mmHg
Baseline 81+12 78+10 0.350
6 months 77+9 77+10 0.961
BP, blood pressure.
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compared with the placebo group (13 subjects, 22.0%). Adverse
events caused study drug withdrawal in nine patients in the nebivo-
lol group and none in the placebo group (Figure 1).
Discussion
ELANDD is the first prospective double-blind placebo-controlled
study to assess the effect of long-term treatment with a beta-
blocker, nebivolol, on exercise capacity in patients with HFPEF.
Compared with placebo, 6 months treatment with nebivolol had
no favourable effect on exercise performance, assessed either by
the 6MWTD (primary endpoint of the study) or cardiopulmonary
exercise testing, with, actually, a lower increase from baseline in
the 6MWTD with nebivolol vs. placebo. The reduction in peak
exercise heart rate after nebivolol administration was related to
the changes in peakVO2, thus suggesting that the inhibition of
the chronotropic response to exercise is the main cause of the
lack of beneficial effects of nebivolol administration on exercise
performance.
Nebivolol is a third-generation beta-blocking agent with asso-
ciated NO-releasing properties. This mechanism causes a
concomitant peripheral vasodilation with improved aortic and
ventricular compliance and, probably, better LV filling.6,18,19,21
On the basis of these findings, we hypothesized that nebivolol
administration could be associated with an improvement in exer-
cise capacity in patients with HFPEF.25 Our study has not proven
this hypothesis, showing that nebivolol administration has no
favourable effect on exercise capacity in patients with HFPEF, com-
pared with placebo. These data with nebivolol are consistent with
the findings with beta-blocker therapy in healthy subjects,28,29
hypertensive patients,30 and patients with HF.16,27,31
The lack of improvement in exercise capacity, despite the bene-
ficial effects on LV function, with beta-blocker therapy in patients
with HF is probably caused by the inhibition of the chronotropic
response to exercise. A correlation between the decrease in
peak exercise heart rate and the change in peak exercise capacity
has been shown in HF patients after beta-blocker therapy.16,31 Our
study shows, for the first time, such a correlation also in patients
with HFPEF. Patients with HFPEF have an increased dependency
on the chronotropic response to exercise,32–34 and, thus, they
could be even more sensitive to the negative chronotropic
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 3 Effects on exercise testing
Variable Nebivolol Placebo P-value
Baseline 6 months Baseline 6 months
6MWTD, m 420+143 428+141 412+123 446+119** 0.004
Peak VO2, mL/kg/min 17.02+4.79 16.32+3.76 17.79+5.96 18.59+5.64 0.63
Exercise duration, s 634+274 564+247 633+250 569+288 0.627
Peak workload, W 98.6+34.6 92.7+30.5 99.5+38.3 103.3+37.4 0.714
Heart rate, b.p.m.
Rest 76+15 68+10** 78+13 80+16 ,0.001
Peak exercise 127+24 17+21* 132+21 134+20 0.065
Systolic BP, mmHg
Rest 128+17 122+18* 129+23 126+22 0.497
Peak exercise 176+29 167+31* 180+34 182+26 0.382
Diastolic BP, mmHg
Rest 80+11 76+12** 78+9 78+10 0.07
Peak exercise 90+12 87+12 89+16 87+15 0.797
Asterisks after the numbers indicate P-values for changes from baseline: *P ,0.05 vs. baseline; **P ,0.001 vs. baseline.
P-values in the last column indicate between ¼ group differences with respect to the changes from baseline in each study group.
BP, blood pressure.
Figure 2 Correlation between changes in peak heart rate
(Delta Peak HR) and peak oxygen consumption ( Delta Peak
VO2) measured with cardiopulmonary exercise testing after 6
months nebivolol treatment. r ¼ 0.391, P ¼ 0.003 for
intention-to-treat analysis; r ¼ 0.452, P ¼ 0.004 for on-treatment
analysis.
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effects of beta-blocker treatment. Other mechanisms, unrelated to
the inhibition of cardiac chronotropic responsiveness by nebivolol,
may have equally contributed to the results of this study. For
example, in a recent study it was shown that nebivolol delays
the onset of myocardial relaxation, at least in mouse myocardium,
thereby prolonging systolic activity, but shortening diastolic filling
time.35 In addition, the higher prevalence of patients with concomi-
tant COPD in the nebivolol group, compared with placebo, may
have also partially contributed to these results. Cardiopulmonary
exercise testing could be terminated because of either limiting
dyspnoea or fatigue. The reason for exercise test termination
was not formally assessed in our study. However, no interaction
with COPD was found.
Lastly, it must be noted that our patients had only mild LV
diastolic dysfunction and only a mild exercise limitation. Namely,
78% of our patients were in NYHA functional class II, mean
6MWTD was 414+135 m, and median NT-proBNP plasma
levels were only 131 pg/ mL (range 9–3577 pg/mL). Thus, it may
be that our patients were not sick enough to benefit from the
beneficial effects of NO release and beta-blockade. Similar limita-
tions have been described in larger studies of patients with
HFPEF.36
Our results are seemingly in contrast to a previous single-centre
study, involving 26 patients, showing an improvement in exercise
capacity with nebivolol compared with placebo in patients with
HFPEF,24 as well with data showing a favourable effect of NO
release on LV diastolic function,21 a known determinant of exercise
capacity. In the previous study, however, nebivolol was compared
with another beta-blocker, atenolol, and, accordingly, the magni-
tude of the reduction of heart rate at peak exercise was similar
with both compounds.24 Thus, it may be hypothesized that NO
release by nebivolol administration may allow a better exercise
tolerance compared with other beta-blockers, though not if com-
pared with placebo, or, probably, other classes of drugs.
Nebivolol has been shown to have favourable effects on out-
comes in patients with an LVEF .0.35.11 Our results do not
contradict this study. The beneficial effects of beta-blockers on
outcomes are mediated by their favourable effects on LV remod-
elling and the cardiomyocytes, whereas the effects on exercise
capacity depend on the heart rate response to exercise.16
In our study, 9 of 57 patients (15.7%) randomized to nebivolol
were withdrawn from the study for lack of tolerance of the
target dose of 5 mg daily (Figure 1). This proportion seems large;
however, these data compare favourably with recent data in
patients aged ≥65 years.37
In conclusion, long-term nebivolol administration did not favour-
ably affect exercise performance, compared with placebo, in a
group of patients with HFPEF. Changes in peak exercise capacity
were related to reduced heart rate response to exercise.
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